The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Surgical Management of Primary Pulmonary Carcinoid Tumors

Authors: Jordan M. Howard, BHSc, Sibu P. Saha, MD

Abstract

Objective: Primary pulmonary carcinoid tumors constitute 1% to 2% of primary lung neoplasms, with limited surgical outcome data due to the rarity of these neoplasms. The aim of our study was to review the complications and long-term outcomes following surgery for primary pulmonary carcinoid neoplasms.

Methods: With institutional review board approval, the charts of patients with lung neoplasms from 2000–2022 were reviewed. In total, 605 total charts were reviewed, with 535 excluded for not having a primary pulmonary carcinoid tumor or not receiving surgical treatment. Typical, atypical, and cumulative survival rates were calculated along with complications.

Results: Major presenting symptoms included 31% (n = 22) persistent cough, 30% (n = 21) dyspnea, 9% (n = 6) hemoptysis, and 7% (n = 5) constitutional symptoms (fever, weight loss, and/or night sweats). Fifty-one percent (n = 36) were found incidentally, and 14% (n = 10) had unknown presentation. There were complications in 26 patients (41%). Minor complications included chest wall pain (n = 6), chest tube air leak (n = 4), dyspnea (n = 3), atelectasis (n = 2), ileus (n = 2), postpneumonectomy syndrome (n = 1), and chronic cough (n = 1). Serious complications included atrial fibrillation (n = 2), respiratory failure (n = 1), hemothorax (n = 1), hypovolemic shock (n = 1), and intraoperative tension pneumothorax (n = 1). No patients died during surgery or secondary to any complications of surgery.

Outcomes: The cumulative 2-year survival rate was 98.5%, and the cumulative 5-year survival rate was 96.3%. There were seven total deaths during the study period, but the cause of death was not reported.

Conclusions: This study confirms that resection of primary pulmonary carcinoid tumors is relatively low risk, with excellent long-term survival rates.
Posted in: Pulmonary Disease22

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934-959.
 
2. Kneuertz PJ, Kamel MK, Stiles BM, et al. Incidence and prognostic significance of carcinoid lymph node metastases. Ann Thorac Surg 2018;106:981-988.
 
3. Herde RF, Kokeny KE, Reddy CB, et al. Primary pulmonary carcinoid tumor: a long-term single institution experience. Am J Clin Oncol 2018;41:24-29.
 
4. Fox M, Van Berkel V, Bousamra II M, et al. Surgical management of pulmonary carcinoid tumors: sublobar resection versus lobectomy. Am J Surg 2013;205:200-208.
 
5. Randhawa S, Trikalinos N, Patterson GA. Neuroendocrine tumors of the lung. Thorac Surg Clin 2021;31:469-476.
 
6. Thakur S, Florisson D, Telianidis S, et al. Pulmonary carcinoid tumours: a multi-centre analysis of survival and predictors of outcome following sublobar, lobar, and extended pulmonary resections. Asian Cardiovasc Thorac Ann 2021;29:532-540.
 
7. Kasprzyk M, Musiałkiewicz J, Kolasiński M, et al. Pulmonary carcinoids—analysis of early and long-term surgical treatment outcomes in a group of 90 patients. Kardiochir Torakochir Pol 2017;14:225-229.
 
8. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-135.
 
9. Reuling EMBP, Dickhoff C, Plaisier PW, et al. Endobronchial and surgical treatment of pulmonary carcinoid tumors: a systematic literature review. Lung Cancer 2019;134:85-95.
 
10. Saha SP, Rogers AG, Earle GF, et al. Bronchial carcinoid tumor: a retrospective review of 35 patients. Contemp Surg 1996;49:23-24.
 
11. Bernard A, Cottenet J, Pagès PB, et al. Mortality and failure-to-rescue major complication trends after lung cancer surgery between 2005 and 2020: a nationwide population-based study. BMJ 2023;13:e075463.
 
12. Dogru MV, Sezen CB, Aker C, et al. Evaluation of factors affecting morbidity and mortality in pneumonectomy patients. Acta Chir Belg 2020;121:301-307.
 
13. Yoon JY, Sigel K, Martin J, et al. Evaluation of the prognostic significance of TNM staging guidelines in lung carcinoid tumors. J Thorac Oncol 2019;14:184-192.
 
14. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of TNM classification for lung cancer. J Thorac Oncol 2016;11:39-51.
 
15. Baudin E, Caplin M, Garcia-Carbonero R, et al. Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:439-451.